Combined quantitative dynamic contrast-enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer

Journal of Magnetic Resonance Imaging

Volumn 20, Issue 2, 2004, Pages 279-287

  Van Dorsten, Ferdinand A ^a   Van Der Graaf, Marinette ^a   Engelbrecht, Marc R W ^a   Van Leenders, Geert J L H ^a   Verhofstad, Albert ^a   Rijpkema, Mark ^a   De La Rosette, Jean J M C H ^a   Barentsz, Jelle O ^a   Heerschap, Arend ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arterial input function; Dynamic contrast enhanced MRI; MR spectroscopic imaging; Prostate; Tumor

Indexed keywords

CHOLINE; CITRIC ACID; CREATINE; GADOLINIUM PENTETATE; RECOMBINANT GLUCAGON;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MALE; MICROVASCULATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; SIGNAL NOISE RATIO;

AGED; CITRIC ACID; CLINICAL PROTOCOLS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS;

EID: 3242786406     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.20113     Document Type: Article

References (40)

1. Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin North Am 2000;38:59-85.
2. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-232.
3. Heerschap A, Jager GJ, van der Graaf M, et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res 1997;17:1455-1460.
4. Kurhanewicz J, Vigneron DB, Nelson SJ, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995;45:459-466.
5. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996;198:795-805.
6. Liney GP, Turnbull LW, Knowles AJ. In vivo magnetic resonance spectroscopy and dynamic contrast enhanced imaging of the prostate gland. NMR Biomed 1999;12:39-44.
7. Mescher M, Tannus A, Johnson MO, Garwood M. Solvent suppression using selective echo dephasing. J Magn Reson 1996;123:226-229.
8. Star Lack J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 1997;38:311-321.
9. Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn Reson Med 1990;14:26-30.
10. Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H, Kramer J. Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med 1994;31:567-571.
11. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging 2001;14: 457-463.
12. Larsson HB, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med 1990;16: 117-131.
13. Van den Boogaart A. MRUI Manual V.96.3. A user's guide to the Magnetic Resonance User Interface Software Package. Delft: Delft Technical University Press; 1997.
14. Pijnappel WWF, Van den Boogaart A, De Beer R, Van Ormond D. SVD-based quantification of magnetic resonance signals. J Magn Reson 1992;97:122-134.
15. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997;129:35-43.
16. van der Graaf M, Jager GJ, Heerschap A. Removal of the outer lines of the citrate multiplet in proton magnetic resonance spectra of the prostatic gland by accurate timing of a point-resolved spectroscopy pulse sequence. MAGMA 1997;5:65-69.
17. Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, Ruijs SH. Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn Reson Med 1997;37:204-213.
18. van der Sanden BP, Rozijn TH, Rijken PF, et al. Noninvasive assessment of the functional neovasculature in 9L-glioma growing in rat brain by dynamic 1H magnetic resonance imaging of gadolinium uptake. J Cereb Blood Flow Metab 2000;20:861-870.
19. Huch Boni RA, Boner JA, Lutolf UM, Trinkler F, Pestalozzi DM, Krestin GP. Contrast-enhanced endorectal coil MRI in local staging of prostate carcinoma. J Comput Assist Tomogr 1995;19:232-237.
20. Jager GJ, Ruijter ET, van de Kaa CA, et al. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 1997; 203:645-652.
21. Engelbrecht M, Huisman HJ, Laheij RJF, et al. Discrimination of prostate cancer from peripheral zone and central gland tissue using dynamic contrast-enhanced MR imaging. Radiology 2003;229: 248-254.
22. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000;55:99-109.
23. Galbraith SM, Lodge MA, Taylor NJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002;15:132-142.
24. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002:15:154-163.
25. Zhu XP, Li KL, Kamaly-Asl ID, et al. Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2± contrast-enhanced dynamic MR imaging. J Magn Reson Imaging 2000;11:575-585.
26. Turnbull LW, Buckley DL, Turnbull LS, Liney GP, Knowles AJ. Differentiation of prostatic carcinoma and benign prostatic hyperplasia: correlation between dynamic Gd-DTPA-enhanced MR imaging and histopathology. J Magn Reson Imaging 1999;9:311-316.
27. Muramoto S, Uematsu H, Kimura H, et al. Differentiation of prostate cancer from benign prostate hypertrophy using dual-echo dynamic contrast MR imaging. Eur J Radiol 2002:44:52-58.
28. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991:17:357-367.
29. Padhani AR, Hayes C, Landau S, Leach MO. Reproducibility of quantitative dynamic MRI of normal human tissues. NMR Biomed 2002;15:143-153.
30. Vonken EP, van Osch MJ, Bakker CJ, Viergever MA. Simultaneous quantitative cerebral perfusion and Gd-DTPA extravasation measurement with dual-echo dynamic susceptibility contrast MRI. Magn Reson Med 2000;43:820-827.
31. Van Laarhoven HWM, Rijpkema M, Punt CJA, et al. Method for quantification of dynamic MRI contrast agent uptake in colorectal liver metastases. J Magn Reson Imaging 2003;18:315-320.
32. Costello LC, Franklin RB. Citrate metabolism of normal and malignant prostate epithelial cells. Urology 1997;50:3-12.
33. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 1999;213:473-480.
34. Scheenen TWJ, Klomp DWJ, Röll S, Fütterer JJ, Barentsz JO, Heerschap A. Fast acquisition weighted three-dimensional spectroscopic imaging of the human prostate. Magn Reson Med 2004:52: 80-88.
35. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(3 Suppl):933-938.
36. Parivar F, Hricak H, Shinohara K, et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy, Urology 1996;48:594-599.
37. Mueller-Lisse UG, Swanson MG, Vigneron DB, et al. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 2001;46:49-57.
38. Mueller-Lisse UG, Vigneron DB, Hricak H, et al. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study, Radiology 2001;221:380-390.
39. Zaider M, Zelefsky MJ, Lee EK, et al. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2000;47:1085-1096.
40. Padhani AR, MacVicar AD, Gapinski CJ, et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology 2001;218:365-374.